Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 20/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 20/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 20/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818569 | 1.00 | HDAC3 (1.00) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14408149 | 0.93 | HDAC1 (0.88) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14408147 | 0.90 | HDAC1 (0.82) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14408105 | 0.90 | HDAC1 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8276109 | 0.90 | HDAC1 (0.81) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8273338 | 0.88 | HDAC1 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8274586 | 0.88 | HDAC1 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14408157 | 0.88 | HDAC1 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14408148 | 0.88 | HDAC1 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL8274492 | 0.88 | HDAC3 (0.79) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470722-B2 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7381749-B2 | Sulfonamides as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7271195-B2 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271195-B2 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271195-B2 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1635800-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005120515-A2 | NOVEL SULFONAMIDES AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2004110418-A2 | CARBONYL COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026907-A1 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC5, HDAC1 | HDAC3 4/4885HDAC4 8/4885HDAC1 3/4885 |
| US-20060030554-A1 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | HDAC3 2/4885HDAC4 7/4885HDAC1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.